Patient P-02546
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
91%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S20
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −26% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 69 SC-12 recommended — Supportive Compound SC-12
- Day 70 Patient accepted — Started SC-12 in the companion
- Day 76 No meaningful change — Supportive Compound SC-12
- Day 82 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 82.
Primary contributors, last 14 days
- Treatment adherence+12
- Inflammatory activity+10
- Toxicity+10
- GI instability+4
- Nutritional resilience-4
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −26%
- Supportive Compound SC-12Day 69Result: no meaningful change
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 67 and rising
- WearableSleep 5.2 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 38/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓45
- WearableResting HR 86 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.8 · butyrate capacity 38/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 45 ms
- Sleep
- 4.7 h
- Steps
- 4,194
- Resting HR
- 88 bpm
Daily log: GI score 67, nutritional resilience 35, adherence 48.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02594 | 57% | S20 | — | — | 45 |
| P-02657 | 52% | S14 | — | — | 42 |
| P-02253 | 51% | S14 | NP-02 | no change | 41 |
| P-02514 | 51% | S05 | ME-01 | improved | 44 |
| P-02039 | 50% | S14 | — | — | 38 |
| P-02320 | 50% | S14 | NP-02 | improved | 50 |
| P-02340 | 49% | S14 | NP-02 | no change | 46 |
| P-02348 | 48% | S14 | GI-04 | improved | 49 |
| P-02628 | 48% | S14 | SC-12 | improved | 47 |
| P-02059 | 47% | S03 | SC-12 | improved | 41 |
| P-02511 | 47% | S04 | — | — | 51 |
| P-02535 | 47% | S14 | SC-12 | improved | 50 |